Abstract Background-Although sulindac is known to cause regression of colorectal adenomatous polyps in familial adenomatous polyposis, less is known about the effect of sulindac on sporadic adenomas. The precise mechanisms of these effects also remain to be determined. Aimn-Sulindac was given to patients with sporadic colorectal adenomatous polyps to evaluate its effects on them, and histological analysis was performed to elucidate the mechanism of the polyp regression, as well the kind of adenomatous polys that are susceptible to the agent.
Subjects-20 adenomatous polyps in 15 patients were studied. Methods-Sulindac (300 mg daily) was given for four months, followed by colonoscopy with removal of the residual polyps. Polyp size, degree of atypia, inflammatory cell infiltration in the polyps, and immunostaining for mutant p53 product were evaluated before and after treatment.
Results-13 of the 20 polyps shrank or disappeared. Patient sex, polyp location, size, degree of atypia, or p53 mutation did not affect the response, but polyps in older patients were more sensitive to sulindac. The degree of atypia or inflammatory cell infiltration was not affected by the treatment. A polyp containing a focal cancer was unresponsive. Conclusions-Sulindac can cause regression of sporadic colorectal adenomatous polyps.
(Gut 1997; 40: 344-349) significant regression of sporadic colonic polyps.""'6 However, no essential differences between adenomatous polyps in FAP and sporadic polyps are known, both histologically and genetically.'7 Therefore, because sulindac is known to have a regressive effect on FAP polyps, an anti-adenomatous polyp effect of sulindac in sporadic polyps might be expected. We studied the treatment of sporadic colorectal polyps with this agent in another population.
Methods

Patients
The patients (11 men age (mean (SD)), 56-9 (7-6) years old) were treated at Tokyo University Hospital. Patients in whom one or more colorectal polyps were diagnosed by barium enema studies subsequently underwent colonoscopy, and biopsy specimens of the colorectal polyps were obtained. Patients whose polyps proved to be adenomas on histological examination were included in the study. No patient had FAP or Lynch syndrome (hereditary non-polyposis colorectal cancer) -that is, all patients had less than 10 polyps and no patient met the criteria for Lynch syndrome. ' Three polyps were located in the right side colon (ascending and transverse colon) and 17 in the left side (descending and sigmoid colon, and rectum), and response did not differ significantly according to the location of the polyps (Table II) .
There was also no significant difference in the mean original diameters of polyps responsive and unresponsive to sulindac treatment (8-9 and 10-3 mm, respectively; Table III (Table III) . Changes in atypia were evaluated in the 10 polyps in which histological examination was available both before and after the treatment. In the three sulindac responsive polyps, the atypia did not change after treatment. However, among the seven unresponsive polyps, two showed an increase in the degree of atypia.
Infiltrating cell numbers Numbers of infiltrating mononuclear cells in lamina propria mucosae of adenomas slightly decreased after the treatmnent (mean (SEM)) (before; 43 (9) and after; 41 (9) , but the difference was not statistically significant (Table II) .
Pre-treatment infiltrating mononuclear cell numbers of responsive and unresponsive polyps were 45 (13) and 46 (7), respectively (Table III) , and the infiltrating cell number did not have any influence on polyp regressive effect.
p53 Staining On immunohistochemical examination for mutant p53 product, five were positive and 14 were negative at the beginning. Three of five p53 positive polyps and nine of 14 negative ones responded to the treatment, and there was no correlation between p53 positivity and sulindac responsiveness. As described above, subsequent to treatment, 13 of 20 polyps tested had a greater than 40% loss in polyp diameter. Remarkably, nine of 13 polyps had completely disappeared on colonoscopic examination. These results show that sulindac has a regressive effect on sporadic adenomatous polyps, at least in some patients.
Discussion
Certain hypotheses on the mechanism of polyp regression by sulindac have been postulated,'5 38A1 but the precise mechanism of action is not yet known. As a polyp consists of adenoma cells and interstitial components such as infiltrating cells or connective tissues, or both, reduction in polyp size would have to be the result of a decrease in either or both of these components. Therefore, a possibility that a reduction in components other than adenoma cells, such as inflammatory cells, contributes to polyp shrinkage, has not been ruled out. This is especially noteworthy in light of the fact that sulindac is an anti-inflammatory drug. Therefore, histological changes induced by the treatment were investigated. However, no significant changes in inflammatory cell numbers could be detected. Therefore, it seems that the cause of decrease in polyp size was not inflammatory cell depletion. On the other hand, the interstitial tissues of the polyps (oedema, fibrous tissues, or haemorrhage) did not change significantly either (data not shown). Therefore, polyp regression is histologically suggested to be due to adenoma cell depletion. Histological examination failed to show any decrease in the degree of atypia in sulindac treated polyps. This implies that the anti-polyp effect was not associated with induction of differentiation.
It is possible, of course, that a certain subpopulation of polyps or polyps at a certain stage'7 are susceptible to the drug. In this regard, we have investigated predisposing factors including patient age and sex, polyp location, degree of atypia, polyp size, mononuclear cell infiltration into lamina propria mucosae, and mutant p53 product via immunostaining, in relation to the responses to treatment (Table III) Concerning the degree of atypia, there was no statistically significant difference in responses between adenomas with mild atypia and moderate atypia, and both types of adenomas responded to the treatment. None of the polyps were judged to be adenomas with severe atypia before treatment, but in this study, the only polyp that proved to contain a tiny focal cancer at the end of the treatment, did not respond to the treatment. Established cancers may not be sensitive to the drug. No significant difference in mononuclear cell infiltration was noted in relation to responsiveness to sulindac.
Little is known about the effects of sulindac on cancer related gene products, but an abstract reports that sulindac reduces the levels of mutant p53.43 This change may be related to anti-neoplastic properties of the drug. Mutated p53 product was examined by immunohistochemical staining in this study to see whether changes in p53 expression is taking place in the treatment course, and whether p53 mutation is a predisposing factor for response to sulindac. However, it was hard to evaluate changes in mutant p53 levels induced by sulindac, because only three polyps were positive for p53 before the treatment. Both p53 positive and negative polyps responded to the drug. However, as positive staining in a colorectal adenoma is often focal,44 as seen in several polyps tested in this study (data not shown), and specimens stored at room temperature for months may lose immunoreactivity to antip53 antibodies,45 further investigations are necessary to elucidate the role of p53 in the sulindac induced polyp regression. Thus, the results of p53 analysis in this study were inconclusive and the possibility of a p53 gene alteration in sulindac induced adenoma regression cannot be ruled out.
Regression of colorectal adenomas would be of especially great benefit if such polyp regression could really lead to cancer prevention. Animal experiments46-55 as well as epidemiological studies3133 suggest that NSAIDs do have a colorectal cancer preventive effect, but on the other hand, rectal cancers are reported to occur in FAP patients treated with sulindac. 56 57 In this regard, it is noteworthy that an adenomatous polyp containing a focal cancer did not respond to sulindac, and that some of non-reponsive polyps exhibited increases in atypia after sulindac therapy in this study. The degree of atypia before treatment did not affect response to sulindac in this study, but it should be noted that adenomas with severe atypia were excluded. The effect of sulindac on adenomas with severe atypia remains to be elucidated, and longer observation of FAP patients treated wih sulindac is necessary.
Irrespective of the cancer preventive effect, medical reduction of colorectal polyp size by sulindac should be of benefit in reducing risks associated with polypectomy procedures. Large polyps are generally associated with higher risks of complications such as bleeding or intestinal perforation. Indeed, in this study, a polyp originally 28 mm in size in a patient could be resected very easily, because the polyp diameter decreased dramatically to 8 mm (patient G). Thus, sulindac may prove to be the drug of choice in mass reduction of adenomatous polyps prior to endoscopic polypectomy, especially in large polyps.
The optimal dose of sulindac in colorectal adenoma treatment remains to be determined.
For example, the dose of aspirin required for inhibition of platelet aggregation is known to be much lower than that for analgesic or antipyretic use. We administered 300 mg of sulindac per day, a common dose when used as an anti-inflammatory or analgesic drug, but epidemiological studies show that low doses of NSAIDs seem to be effective in colorectal cancer prevention. 36 The dose of sulindac required for adenomatous polyp regression may be lower than that adopted in this and previous studies. In fact, a recent study reported a rectal polyp regressive effect with a low dose sulindac suppository ( 
